Efficacy of methylprednisolone versus other pharmacologic interventions for the treatment of central post-stroke pain: a retrospective analysis

Anthony J Pellicane
Scott R Millis
Department of Physical Medicine and Rehabilitation, Wayne State University School of Medicine, Rehabilitation Institute of Michigan in the Detroit Medical Center, Detroit, MI, USA

Purpose: To determine if an oral, tapered methylprednisolone regimen is superior to other commonly used pharmacologic interventions for the treatment of central post-stroke pain (CPSP).

Patients and methods: In this study, the charts of 146 stroke patients admitted to acute inpatient rehabilitation were retrospectively reviewed. Patients diagnosed with CPSP underwent further chart review to assess numerical rating scale for pain scores and as-needed pain medication usage at different time points comparing CPSP patients treated with methylprednisolone to those treated with other pharmacologic interventions.

Results: In the sample, 8.2% were diagnosed with CPSP during acute care or inpatient rehabilitation. Mean numerical rating scale for pain scores day of symptom onset did not differ between those patients treated with methylprednisolone versus those treated with other pharmacologic interventions (mean ± standard deviation; 6.1 ± 2.3 versus 5.7 ± 1.6, P = 0.77). However, mean numerical rating scale for pain scores differed significantly 1-day after treatment initiation (1.7 ± 2.1 versus 5.0 ± 1.9, P = 0.03) and 1-day prior to rehabilitation discharge (0.3 ± 0.9 versus 4.1 ± 3.2, P = 0.01) between the two groups. Compared to day of symptom onset, as-needed pain medication usage within the methylprednisolone group was marginally less 1-day after treatment initiation (Z = −1.73, P = 0.08) and 1-day prior to rehabilitation discharge (Z = −1.89, P = 0.06). No difference in as-needed pain medication usage existed within the non-steroid group at the same time points.

Conclusion: Methylprednisolone is a potential therapeutic option for CPSP. The findings herein warrant study in prospective trials.

Keywords: stroke, pain, central post-stroke pain, complex regional pain syndromes, therapeutics, neuralgia

Introduction

Central post-stroke pain (CPSP) can be defined as a central neuropathic pain condition occurring after stroke located in the body part(s) corresponding to a cerebrovascular lesion of the somatosensory system characterized by pain and sensory abnormalities where other causes of obvious nociceptive, psychogenic, or peripheral pain have been excluded.1,2 The prevalence and yearly incidence of CPSP has been reported as 7.3% and 8%, respectively.2,3 CPSP is considered challenging from a clinical management standpoint and existing treatment options do not result in optimal outcomes.4 One author describes CPSP as an under-recognized complication of stroke despite its potential to impair activities of daily living, deteriorate quality of life, and undermine rehabilitation efforts, and states that CPSP has an overall immense and devastating burden on patients and society.2 Post-stroke complex regional pain syndrome (CRPS) shares...
similar pain characteristics with CPSP, however, post-stroke CRPS also presents with extremity edema and dystrophic skin changes with temperature and color abnormalities.\textsuperscript{6} The pathophysiology underlying CPSP and post-stroke CRPS is not understood; however, these two diagnoses share the possible pathophysiologic process of central sensitization resulting in hyperexcitability of central nociceptive neurons.\textsuperscript{7,6}

Given that corticosteroids may regulate the levels of excitatory neuropeptides that contribute to central sensitization and neuronal hyperexcitability,\textsuperscript{7} Braus et al performed a randomized, non-blinded, placebo-controlled trial assessing the efficacy of an oral, tapered methylprednisolone regimen in the treatment of post-stroke CRPS.\textsuperscript{3} In this study, 91.2\% of patients diagnosed with post-stroke CRPS became symptom free (in an average of 10 days after treatment initiation) and remained symptom free at 6-month follow-up after treatment with the steroid and physical therapy. Similarly, in a randomized, double-blind, active-placebo controlled trial, Kalita et al demonstrated significant improvement in 83.3\% of post-stroke CRPS patients treated with an oral, tapered prednisolone regimen versus only 16.7\% of patients treated with piroxicam.\textsuperscript{8} Given the positive results from these two studies, the overlap in pathophysiology between CPSP and post-stroke CRPS, and the difficulties clinicians face in the treatment of CPSP, the retrospective study described herein was initiated in an attempt to assess the efficacy of methylprednisolone versus other pharmacologic interventions for the treatment of CPSP.

It was hypothesized that methylprednisolone would be superior to other pharmacologic interventions for the treatment of CPSP in the acute rehabilitation inpatient with regard to reduction in numerical rating scale for pain scores (NRS) and as-needed pain medication usage. We have no knowledge of any previously published studies that describe the treatment of CPSP with an oral steroid.

**Material and methods**

This study was approved by the Wayne State University Institutional Review Board in Detroit, Michigan. All patients admitted to an acute inpatient rehabilitation facility after acute stroke between January 7, 2010 and June 30, 2011 were studied retrospectively. Patients documented as being diagnosed with CPSP during acute care or acute inpatient rehabilitation underwent chart, vital signs, and medical administration record review in order to obtain demographic information (age, gender, race), stroke type, past medical history, symptom onset (days post-stroke), pharmacologic intervention(s), 11-point NRS on day of symptom onset, NRS 1-day after treatment initiation, subjective pain reports 1-day after treatment initiation, NRS 1-day prior to rehabilitation discharge, as-needed pain medication usage on day of symptom onset, as-needed pain medication usage 1-day after treatment initiation, and as-needed pain medication usage 1-day prior to rehabilitation discharge. Additionally, those patients documented as being diagnosed with CPSP during acute care or acute inpatient rehabilitation underwent chart review of the initial outpatient follow-up appointment after rehabilitation discharge in order to obtain data on subjective pain reports.

The primary outcome measure was mean NRS during inpatient care and the secondary outcome measure was mean as-needed pain medication usage during inpatient care. For each inpatient, the mean NRS was calculated from all pain scores documented in the electronic medical record from 6:00 am to 11:59 pm on the specified day (without regard to documentation of painful area). Similarly, for each patient, mean number of as-needed pain medications used was calculated from all documented as-needed pain medication administrations per the medication administration record from 6:00 am to 11:59 pm on the specified day (without regard to type of as-needed pain medication administered).

In addition to the aforementioned analysis of those patients diagnosed with CPSP during acute care and acute inpatient rehabilitation, the remainder of the study population also underwent additional investigations. Patients documented as being diagnosed with post-stroke CRPS during acute care, during acute inpatient rehabilitation, or at the initial outpatient follow-up appointment after rehabilitation discharge and patients documented as being diagnosed with CPSP at the initial outpatient follow-up appointment after rehabilitation discharge were also studied. These patients (combined with those patients diagnosed with CPSP during acute care or acute inpatient rehabilitation) were studied in order to obtain prevalence and symptom onset data for CPSP and post-stroke CRPS. These patients’ demographic information (age, gender, race), stroke type, and past medical history were also recorded.

**Statistical methods**

Independent \( t \)-tests were used for the between group comparisons for NRS at different time points. The Mann–Whitney \( U \) test was used for the between group comparisons for as-needed pain medication usage at different time points. Paired \( t \)-tests were used for the within group comparisons for NRS at different time points. The Wilcoxon signed rank test was used for the within group comparisons for as-needed
pain medication usage at different time points. Criterion for declaring a statistically significant difference was \( P < 0.05 \). Criterion for marginal significance was \( P < 0.10 \).

## Results

During the study period, 146 patients were admitted to an acute inpatient rehabilitation facility after acute stroke. For the entire sample, demographic data, stroke type, and stroke history is presented in Table 1. Additionally, for those patients diagnosed with CPSP and post-stroke CRPS during the study period, demographic data, stroke type, stroke history, prevalence, symptom onset (days), timing of symptom onset, and location of patient at diagnosis (inpatient versus outpatient), is presented in Table 1. Note that two patients diagnosed with CPSP as an inpatient were later diagnosed with post-stroke CRPS at outpatient follow-up after rehabilitation discharge.

Moving forward, we now focus solely on those patients diagnosed with CPSP during acute care or acute inpatient rehabilitation. Of the sample, 8.2% (\( N = 12 \)) was diagnosed with CPSP during acute care or acute inpatient rehabilitation. Mean onset of symptoms was 12.3 ± 6.5 days (mean ± standard deviation) post-stroke. Patients presented to acute inpatient rehabilitation 8.8 ± 5.1 days after admission to acute care. Two of the twelve patients developed symptoms during their acute care course. Excluding these two patients, acute rehabilitation inpatients developed CPSP 5.0 ± 4.4 days after admission to rehabilitation.

After symptom onset, 7 of the 12 patients diagnosed with CPSP were treated with an oral, tapered methylprednisolone regimen (Medrol Dosepak®; Pfizer Inc., New York, NY, USA) while 5 of the 12 patients received other pharmacologic interventions (these included amitriptyline, fluvoxamine, gabapentin, pregabalin, and lamotrigine in varying combinations). Five of the seven patients who received methylprednisolone did not receive any other treatment for CPSP. The other two methylprednisolone patients received pregabalin and amitriptyline with lamotrigine, respectively. Moving forward, those patients treated with the methylprednisolone taper will be termed the steroid group and those patients treated with other pharmacologic interventions will be termed the non-steroid group. Table 2 details the methylprednisolone taper used. Due to the short duration of the taper, no patients were on methylprednisolone when discharge NRS or discharge as-needed pain medication usage data was collected.

Mean NRS day of symptom onset for the steroid group and non-steroid groups did not differ significantly (6.1 ± 2.3 versus 5.7 ± 1.6, \( t[9] = 0.30, P = 0.77 \)). Mean NRS 1-day after treatment initiation for the steroid group was significantly lower than the mean NRS 1-day after treatment initiation for the non-steroid group (1.7 ± 2.1 versus 5.0 ± 1.9, \( t[9] = -2.55, P = 0.03 \)). Mean NRS 1-day prior to rehabilitation discharge for the steroid group was also significantly lower than the non-steroid group (0.3 ± 0.9 versus 4.1 ± 3.2, \( t[9] = -3.06, P = 0.01 \)). Figure 1 provides

### Table 1 Descriptive data

|                | Entire sample (\( N = 146 \)) | CPSP (\( N = 14 \)) | Post-stroke CRPS (\( N = 8 \)) |
|----------------|-------------------------------|-------------------|-------------------------------|
| Prevalence     | 9.6%                          | 5.5%              |                               |
| Mean age ± SD (years) | 60.3 ± 14.3                  | 49.7 ± 16.9       | 52.9 ± 6.5                    |
| Gender         |                               |                   |                               |
| Male           | 47.9% (70)                    | 49.2% (6)         | 40.0% (3)                     |
| Female         | 52.1% (76)                    | 57.1% (8)         | 60.0% (5)                     |
| Racial background |                               |                   |                               |
| White          | 19.9% (29)                    | 7.1% (1)          | 12.5% (1)                     |
| Black          | 77.4% (113)                   | 71.4% (10)        | 75.0% (6)                     |
| Other          | 2.7% (4)                      | 21.4% (3)         | 12.5% (1)                     |
| Stroke type    |                               |                   |                               |
| Ischemic       | 78.8% (115)                   | 85.7% (12)        | 62.5% (5)                     |
| Hemorrhagic    | 17.8% (26)                    | 14.3% (2)         | 25.0% (2)                     |
| Hemorrhagic conversion | 3.4% (5)                    | 0.0% (0)          | 12.5% (1)                     |
| History of prior stroke |                               |                   |                               |
| Yes            | 21.2% (31)                    | 7.1% (1)          | 50.0% (4)                     |
| No             | 78.8% (115)                   | 92.9% (13)        | 50.0% (4)                     |
| Mean ± SD (days) symptom onset post-stroke | 20.9 ± 27.2 | 55.9 ± 28.7 |  |
| Timing of symptom onset post-stroke |                               |                   |                               |
| ≤30 days       | 92.9% (13)                    | 12.5% (1)         |                               |
| 31–90 days     | 0.0% (0)                      | 75.0% (6)         |                               |
| 91–180 days    | 7.1% (1)                      | 12.5% (1)         |                               |
| Diagnosis made as inpatient | 85.7% (12) | 12.5% (1) |                               |
| Diagnosis made as outpatient | 14.3% (2) | 87.5% (7) |                               |

Abbreviations: CPSP, Central Post-Stroke Pain; SD, standard deviation.

### Table 2 Methylprednisolone taper details

| Timing of prescription | Dose and regimen |
|------------------------|------------------|
| Methylprednisolone Day 1: 12 mg with lunch, 4 mg with dinner, and 8 mg at night taper prescribed | Day 2: 4 mg with each meal and 8 mg at night before |
|                        | Day 3: 4 mg with each meal and 4 mg at night |
|                        | Day 4: 4 mg with each meal |
|                        | Day 5: 4 mg with breakfast and dinner |
|                        | Day 6: 4 mg with breakfast |
| Methylprednisolone Day 1: 24 mg one time only taper prescribed | Day 2: 4 mg with each meal and 8 mg at night after 12:00 noon |
|                        | Day 3: 4 mg with each meal and 4 mg at night |
|                        | Day 4: 4 mg with each meal |
|                        | Day 5: 4 mg with breakfast and dinner |
|                        | Day 6: 4 mg with breakfast |
a visual representation of these results. Table 3 details the percent reduction in NRS for the steroid and non-steroid groups 1-day after treatment initiation and 1-day prior to rehabilitation discharge compared to day of symptom onset. Evaluation of subjective pain reports in the daily progress notes 1-day after treatment initiation revealed that five of seven (71.4%) patients in the steroid group reported no pain compared to none (0.0%) of the patients in the non-steroid group. As-needed pain medication usage one day after treatment initiation for the steroid and non-steroid groups did not differ significantly ($U = 10.5, P = 0.27$). The steroid group demonstrated marginally significantly lower as-needed pain medication usage 1-day prior to rehabilitation discharge compared to the non-steroid group ($U = 6.0, P = 0.07$).

For the steroid group, mean NRS day of symptom onset compared to 1-day after treatment initiation differed significantly ($6.1 \pm 2.3$ versus $1.7 \pm 2.1, t[6] = 4.98, P = 0.002$) and mean NRS day of symptom onset compared to 1-day prior to rehabilitation discharge also differed significantly ($6.1 \pm 2.3$ versus $0.3 \pm 0.9, t[6] = 5.88, P = 0.001$). For the non-steroid group, mean NRS day of symptom onset compared to 1-day after treatment initiation ($5.7 \pm 1.6$ versus $5.0 \pm 1.9, t[3] = 1.20, P = 0.32$) and compared to 1-day prior to rehabilitation discharge ($5.7 \pm 1.6$ versus $4.1 \pm 3.2, t[3] = 1.85, P = 0.16$) did not differ significantly. For the steroid group, as-needed pain medication usage day of symptom onset compared to 1-day after treatment initiation ($Z = -1.73, P = 0.08$) and compared to 1-day prior to rehabilitation discharge ($Z = -1.89, P = 0.06$) were marginally significantly different. For the non-steroid group, as-needed pain medication usage day of symptom onset compared to 1-day after treatment initiation ($Z = -1.13, P = 0.26$) and compared to 1-day prior to rehabilitation discharge ($Z = -1.07, P = 0.29$) did not differ significantly.

Six of the 12 patients diagnosed with CPSP during acute care or acute inpatient rehabilitation followed-up as outpatients after discharge from acute inpatient rehabilitation. Of these six, three patients were in the steroid group and three patients were in the non-steroid group. Two of the three steroid group patients reported no pain at outpatient follow-up. The other steroid group patient’s pain was deemed musculoskeletal. All three patients in the non-steroid group reported pain at outpatient follow-up. One of the non-steroid group patient’s pain was deemed musculoskeletal. The other two non-steroid group patients were diagnosed with post-stroke CRPS at outpatient follow-up.

**Discussion**

The prevalence and yearly incidence of CPSP has been reported as 7.3% and 8%, respectively$^{2,3}$ and the majority of patients are diagnosed with CPSP within 3 months of stroke with immediate and delayed onset (>1 year) being possible but atypical.$^{2,3,10–12}$ Fitting with existing literature, the study described here reports a 9.6% prevalence of CPSP with 92.9% of CPSP patients developing symptoms 30 days or less post-stroke (Table 1). The occurrence and timing of post-stroke CRPS is less clearly defined. For example, McLean studied stroke rehabilitation inpatients admitted over a 1-year period and diagnosed post-stroke CRPS in only 1.5% of patients.$^{13}$ However, in this study, diagnosis required a positive bone scan which may have resulted in under-diagnosis. Similarly, in another study by Davis et al, 12.6% of ischemic stroke rehabilitation inpatients were diagnosed with CRPS with most patients developing signs and symptoms between

![Figure 1](image.png)

**Figure 1** NRS for pain at different time points.

**Abbreviation:** NRS, Numerical Rating Scale for pain scores.
The seminal works that helped to establish these assertions were performed by Leijon et al, Vestergaard et al, and Kim et al. For amitriptyline, a randomized, blinded, crossover, placebo-controlled trial demonstrated that 75 mg daily of the tricyclic antidepressant yielded significantly lower mean daily pain ratings on a 10-step verbal scale compared to placebo (4.2 ± 1.6 versus 5.3 ± 2.0 by week 4 of the treatment period); and, perhaps more importantly, 67% of the amitriptyline patients reported improvement in pain on global assessment compared to only 7% of the placebo group. For lamotrigine, a randomized, blinded, crossover, placebo-controlled trial demonstrated that a 200 mg daily dose of the anticonvulsant resulted in significantly lower median daily pain ratings on an 11-point Likert scale compared to placebo (5 versus 7) after 8 weeks of medication titration; however, only 44% of patients were deemed clinical responders (defined by a lamotrigine pain score ≥2 points lower than the corresponding placebo value). For pregabalin, a randomized, blinded, parallel group, placebo-controlled trial assessed the efficacy of 150 mg to 600 mg per day of the anticonvulsant in 219 patients with CPSP. Mean pain score on the Daily Pain Rating Scale decreased in both groups; however, there was no significant difference between the two groups at baseline or endpoint (6.5 to 4.9 in the pregabalin group; 6.3 to 5.0 in the placebo group). Additionally, the majority of patients treated with pregabalin did not achieve a 30% or 50% reduction in mean pain score compared to baseline. However, the pregabalin group did improve significantly over the placebo group in some of the secondary outcome measures including those regarding sleep and anxiety, and on the Clinician Global Impression of Change rating scale. In comparison to these studies, a short, oral, tapered methylprednisolone regimen appears to be far superior for the treatment of CPSP with regard to absolute reduction and rate of reduction in a pain scale score. Further, the percentage of methylprednisolone-treated patients with ≥30%, ≥50%, and 100% reductions in NRS at different time points is remarkable compared to: (1) the non-steroid patient treated patients in this study, (2) the aforementioned pregabalin study, and (3) existing literature commenting on clinically meaningful percent reduction in pain scores. Additionally, the NRS scores 1-day prior to rehabilitation discharge and the subjective pain reports noted at outpatient follow-up suggests long-term benefit for CPSP patients treated with methylprednisolone. The authors are unaware of any existing literature investigating changes in as-needed pain medication usage in response to treatment in patients with CPSP. Here, within

Table 3 Percentage of patients with different percent reductions in NRS at different time points for the steroid and non-steroid groups

| NRS day of symptom onset to 1-day after treatment initiation | Steroid group | Non-steroid group |
|-------------------------------------------------------------|--------------|------------------|
| ≥30% reduction                                             | 100.0%       | 25.0%            |
| ≥50% reduction                                             | 71.4%        | 0.0%             |
| 100% reduction                                             | 42.9%        | 0.0%             |

| NRS day of symptom onset to 1-day prior to rehabilitation discharge | Steroid group | Non-steroid group |
|------------------------------------------------------------------|--------------|------------------|
| ≥30% reduction                                             | 100.0%       | 25.0%            |
| ≥50% reduction                                             | 100.0%       | 25.0%            |
| 100% reduction                                             | 85.7%        | 25.0%            |

Abbreviation: NRS, Numerical Rating Scale for pain scores.
the steroid group (but not within the non-steroid group) at different time points, and between the steroid and non-steroid group at discharge, there was less as-needed pain medication usage noted.

Currently, CPSP and post-stroke CRPS are considered distinct diagnoses. Perhaps CPSP and post-stroke CRPS could be considered one diagnosis that exist on a continuum with CPSP representing a more limited and post-stroke CRPS representing a more florid manifestation of the same syndrome. Given that two patients initially diagnosed with CPSP were later diagnosed with post-stroke CRPS in this study may speak to this possibility. Relatedly, the differences in mean symptom onset and timing of symptom onset for CPSP and post-stroke CRPS described in this study (Table 1) may not demonstrate different onset times for two different post-stroke complications. Instead, these differences may represent the time required for a patient to transition from the more limited to the overt presentation of the same diagnosis. The consideration that CRPS possesses a variety of phenotypes is not without precedent and is applicable to this discussion. Specifically, Bruehl et al postulated CRPS as existing in subtypes; namely, a limited neuropathic pain/sensory syndrome, a limited vasomotor syndrome, and a florid syndrome. 23 While their study did not focus on stroke exclusively, it is apparent that their limited neuropathic pain/sensory syndrome might exist on a spectrum that closely approximates CPSP. Given the overlap in proposed pathophysiology underlying these two diagnoses, 4,6,17,28 considering that they may be one diagnosis existing on a continuum is not unreasonable. Additionally, since autonomic dysfunction post-stroke can occur in the absence of CRPS 29 this further blurs the line between CPSP and post-stroke CRPS.

**Conclusion**

This study introduces methylprednisolone as a potential therapeutic option for patients suffering from CPSP. The findings herein warrant study in large prospective clinical trials. Additionally, this study proposes that CPSP and post-stroke CRPS might exist on a continuum given the two diagnoses overlap in pathophysiology and treatment, and since two patients first diagnosed with CPSP later developed post-stroke CRPS. Importantly, it should be noted that both CPSP patients who later developed post-stroke CRPS were not treated with methylprednisolone. This, coupled with the abrupt improvement in NRS noted in the steroid group, might suggest that methylprednisolone has abortive properties in the treatment and prevention of progression of central pain phenomena after stroke.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Kliot H, Finnerup NB, Jensen TS. Central post-stroke pain: clinical characteristics, pathophysiology, and management. *Lancet Neurol*. 2009;8(9):857–868.
2. Kliot H, Finnerup NB, Andersen G, Jensen TS. Central poststroke pain: a population-based study. *Pain*. 2011;152(4):818–824.
3. Andersen G, Vestergaard K, Ingeman-Nielsen M, Jensen TS. Incidence of central post-stroke pain. *Pain*. 1995;61(2):187–193.
4. Harvey RL. Central poststroke pain syndrome. *Top Stroke Rehabil*. 2010;17(3):163–172.
5. Kumar G, Soni CR. Central post-stroke pain: current evidence. *J Neurol Sci*. 2009;284(1–2):10–17.
6. Pertoldi S, Di Benedetto P. Shoulder-hand syndrome after stroke. A complex regional pain syndrome. *Eura Medophysic*. 2005;41(4):283–292.
7. Smith GD, Seckel JR, Sheward WJ, et al. Effect of adrenalectomy and dexamethasone on neuroneptide content of dorsal root ganglia in the rat. *Brain Res*. 1991;564(1):27–30.
8. Braus DF, Krauss JK, Strobel J. The shoulder-hand syndrome after stroke: a prospective clinical trial. *Ann Neurol*. 1994;36(5):728–733.
9. Kalita J, Vajpayee A, Misra UK. Comparison of prednisolone with piroxicam in complex regional pain syndrome following stroke: a randomized controlled trial. *QJM*. 2006;99(2):89–95.
10. Leijon G, Boivie J, Johansson I. Central post-stroke pain – neurological symptoms and pain characteristics. *Pain*. 1989;36(1):13–25.
11. Nasreddine ZS, Saver JL. Pain after thalamic stroke: right thalamocephalic predominance and clinical features in 180 patients. *Neurology*. 1997;48(5):1196–1199.
12. Bowsher D. Central pain: clinical and physiological characteristics. *J Neurol Neurosurg Psychiatry*. 1996;61(1):62–69.
13. McLean DE. Medical complications experienced by a cohort of stroke survivors during inpatient, tertiary-level stroke rehabilitation. *Arch Phys Med Rehabil*. 2004;85(3):466–469.
14. Davis SW, Petirillo CR, Eichberg RD, Chu DS. Shoulder-hand syndrome in a hemiplegic population: a 5-year retrospective study. *Arch Phys Med Rehabil*. 1977;58(8):353–356.
15. Kocabas H, Levendoglu F, Ozerbil OM, Yuruten B. Complex regional pain syndrome in stroke patients. *Int J Rehabil Res*. 2007;30(1):33–38.
16. Goldy NK, Aras M, Yesiltepe E, Koseoglou F. Reflex sympathetic dystrophy in hemiplegia. *Int J Rehabil Res*. 2006;29(4):275–279.
17. Kumar B, Kalita J, Kumar G, Misra UK. Central poststroke pain: a review of pathophysiology and treatment. *Anesth Analg*. 2009;108(5):1645–1657.
18. Fresse A, Husstedt IW, Ringelstein EB, Evers S. Pharmacologic treatment of central post-stroke pain. *Clin J Pain*. 2006;22(3):252–260.
19. Lejon G, Boivie J. Central post-stroke pain – a controlled trial of amitriptyline and carbamazepine. *Pain*. 1989;36(1):27–36.
20. Vestergaard K, Andersen G, Gottrup H, Kristensen BT, Jensen TS. Lamotrigine for central poststroke pain: a randomized controlled trial. *Neurology*. 2001;56(2):184–190.
21. Kim JS, Bashford G, Murphy TK, Martin A, Dvor V, Cheung R. Safety and efficacy of pregabalin in patients with central post-stroke pain. *Pain*. 2011;152(5):1018–1023.
22. Rowbotham MC. What is a “clinically meaningful” reduction in pain? *Pain*. 2001;94(2):131–132.
23. Cepeda MS, Africano JM, Polo R, Alcala R, Carr DB. What decline in pain intensity is meaningful to patients with acute pain? *Pain*. 2003;105(1–2):151–157.
24. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. *Pain*. 2001;94(2):149–158.
25. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. *Arthritis Rheum.* 1995;38(6):727–735.
26. Forouzanfar T, Weber WE, Kessler M, van Kleef M. What is a meaningful pain reduction in patients with complex regional pain syndrome type I? *Clin J Pain.* 2003;19(5):281–285.
27. Bruehl S, Harden RN, Galer BS, Saltz S, Backonja M, Stanton-Hicks M. Complex regional pain syndrome: are there distinct subtypes and sequential stages of the syndrome? *Pain.* 2002;95(1–2):119–124.
28. Chae J. Poststroke complex regional pain syndrome. *Top Stroke Rehabil.* 2010;17(3):151–162.
29. Korpelainen JT, Sotaniemi KA, Myllyla VV. Autonomic nervous system disorders in stroke. *Clin Auton Res.* 1999;9(6):325–333.